Engaging Patients in Smoking Cessation Treatment within the Lung Cancer Screening Setting: Lessons Learned from an NCI SCALE Trial.
Randi M WilliamsEllie EyestoneLaney SmithJoanna G PhilipsJulia M WhealanMarguerite WebsterTengfei LiGeorge LutaKathryn L Taylornull On Behalf Of The Lung Screening Tobacco Health TrialPublished in: Current oncology (Toronto, Ont.) (2022)
Offering smoking cessation treatment at lung cancer screening (LCS) will maximize mortality reduction associated with screening, but predictors of treatment engagement are not well understood. We examined participant characteristics of engagement in an NCI SCALE cessation trial. Eligible LCS patients (N = 818) were randomized to the Intensive arm (8 phone counseling sessions +8 weeks of nicotine replacement therapy (NRT)) vs. Minimal arm (3 sessions + 2 weeks of NRT). Engagement was measured by number of sessions completed (none, some, or all) and NRT mailed (none vs. any) in each arm. In the Intensive arm, those with ≥some college (OR = 2.1, 95% CI = 1.1, 4.0) and undergoing an annual scan (OR = 2.1, 95% CI = 1.1, 4.2) engaged in some counseling vs. none. Individuals with higher nicotine dependence were more likely (OR = 2.8, 95% CI = 1.3, 6.2) to request NRT. In the Minimal arm, those with higher education (OR = 2.1, 95% CI = 1.1, 3.9) and undergoing an annual scan (OR = 2.0, 95% CI = 1.04, 3.8) completed some sessions vs. none. Requesting NRT was associated with more pack-years (OR = 1.9, 95% CI = 1.1, 3.5). Regardless of treatment intensity, additional strategies are needed to engage those with lower education, less intensive smoking histories, and undergoing a first scan. These efforts will be important given the broader 2021 LCS guidelines.
Keyphrases
- smoking cessation
- replacement therapy
- end stage renal disease
- clinical trial
- newly diagnosed
- ejection fraction
- social media
- phase iii
- type diabetes
- study protocol
- chronic kidney disease
- prognostic factors
- open label
- peritoneal dialysis
- risk factors
- combination therapy
- coronary artery disease
- cardiovascular events
- hiv testing